about
Occupation and risk of parkinsonism: a multicenter case-control studyLewy body-like pathology in long-term embryonic nigral transplants in Parkinson's diseaseRandomized trial of the triple monoamine reuptake inhibitor NS 2330 (tesofensine) in early Parkinson's diseaseClinical-Genetic Associations in the Prospective Huntington at Risk Observational Study (PHAROS): Implications for Clinical Trials.Effect of creatine monohydrate on clinical progression in patients with Parkinson disease: a randomized clinical trial.Caffeine and progression of Parkinson diseaseEfficacy of rasagiline in early Parkinson's disease: a meta-analysis of data from the TEMPO and ADAGIO studies.Neurogenic orthostatic hypotension and supine hypertension in Parkinson's disease and related synucleinopathies: prioritisation of treatment targets.Randomized controlled trial of deutetrabenazine for tardive dyskinesia: The ARM-TD study.A novel design of a Phase III trial of isradipine in early Parkinson disease (STEADY-PD III).Double-blind study of pardoprunox, a new partial dopamine agonist, in early Parkinson's disease.Early pharmacologic treatment in Parkinson's disease.Mavoglurant (AFQ056) in combination with increased levodopa dosages in Parkinson's disease patients.Improving symptom control in early Parkinson's diseaseNBI-98854, a selective monoamine transport inhibitor for the treatment of tardive dyskinesia: A randomized, double-blind, placebo-controlled study.Depression in Parkinson's disease.Ropinirole therapy for Parkinson's disease.A double-blind, delayed-start trial of rasagiline in Parkinson's disease.A double-blind, delayed-start trial of rasagiline in Parkinson's disease (the ADAGIO study): prespecified and post-hoc analyses of the need for additional therapies, changes in UPDRS scores, and non-motor outcomes.Association between Hoehn and Yahr, Mini-Mental State Examination, age, and clinical syndrome predominance and diagnostic effectiveness of ioflupane I 123 injection (DaTSCAN™) in subjects with clinically uncertain parkinsonian syndromes.Placebo response in Parkinson's disease: comparisons among 11 trials covering medical and surgical interventions.Sleep attacks and dopamine agonists for Parkinson's disease: what is currently known?Peptidoglycan recognition protein genes and risk of Parkinson's disease.Head injury, α-synuclein Rep1, and Parkinson's disease.Botulinum toxin A for the treatment of cervical dystonia.Essential tremor. Epidemiology, diagnosis, and treatment.Future therapies for Parkinson's disease.Evaluation of rotigotine transdermal patch for the treatment of apathy and motor symptoms in Parkinson's diseaseA(2A) Receptor Antagonism and Dyskinesia in Parkinson's DiseaseCaffeine and Progression of Parkinson Disease: A Deleterious Interaction With CreatineAdenosine A2A receptor antagonists for Parkinson's disease: rationale, therapeutic potential and clinical experience.Levodopa-carbidopa intestinal gel in advanced Parkinson's disease: final 12-month, open-label resultsThe controversy concerning plasma homocysteine in Parkinson disease patients treated with levodopa alone or with entacapone: effects of vitamin status.Duodenal levodopa infusion for the treatment of Parkinson's disease.Advances in the pharmacologic management of early Parkinson disease.Levodopa-carbidopa intestinal gel in advanced Parkinson's disease open-label study: interim results.Levodopa-induced dyskinesia in Parkinson's disease: epidemiology, etiology, and treatment.Role of the pharmacist in the effective management of wearing-off in Parkinson's disease.Optimizing bioavailability in the treatment of Parkinson's disease.Levodopa-induced dyskinesias in Parkinson's disease: etiology, impact on quality of life, and treatments.
P50
Q28258493-8D821541-8AA7-4114-8561-3FE9EF2E83B4Q28275257-09F6ACBF-989C-4CA8-BF8B-852579A7E6ABQ28277445-8C49D68B-4163-442F-9F80-AF58E8CB3D81Q30278084-C6A865C2-A3B3-4255-88BA-45587BECF369Q30407589-24B4052B-5F56-445D-B438-6CA2A75E3F29Q30432945-A06A8929-D0D1-4BC9-8174-6589F16EAA57Q31060186-0C2009F5-4808-428F-A0D5-C0B946E54F49Q33167532-C228DF7B-9FC2-4CA8-B2F6-3582002DC1DDQ33714619-E6E6F774-4D2F-4A50-8F42-43AA07C9BA42Q33753874-A085C0BA-194F-49DC-8D8C-67B59C58B6C3Q34101796-8736F255-65B6-4B51-ACC4-49787E6C7111Q34105038-EECA32AC-05CC-40E9-B1B1-4FDB68151724Q34368806-FD558086-BBD5-4B4C-8C1B-96F6F3A1CE67Q34409267-DE4BB1DD-38FC-418D-9A7A-73CD8093D0DDQ34492934-11874B38-CA57-43D0-8AA5-C3A706E76869Q34508166-4753CECD-B661-4DEB-B497-D5C4F29F1243Q34557072-13B5A912-45E1-4590-9228-EF7E9DA6C9C2Q34612128-A32EC140-FE97-4121-97C0-C86DE977E071Q34628386-1861327D-6DBD-4E80-9B0E-F3CA4F2241C0Q34630647-322DE89F-8037-4A65-B6CB-B4D246E7FAC8Q34743030-BD56D64F-BFCB-450A-9878-041C587B41BFQ35140357-8F691691-5BD0-4DEA-BBD2-CED6A1F4C812Q35170538-650555E7-EFE7-43F0-AB16-644BA2FF3567Q35726904-BA4EB6E5-BC88-46E6-8735-B388411AE16FQ35871899-C6636C91-A228-45D5-9E76-7240E33FA102Q35873899-86D6C9E9-962A-49DF-9569-125E7D68555DQ35926231-CBF3A60F-0BC6-4098-B651-ACD9913B5642Q36042501-428AE1C8-4952-455B-816D-4241A4E0820BQ36057652-143A1D81-4713-478D-9067-53CB5A9CD86DQ36070544-00490202-C04D-4632-BF13-52F8347118A6Q36172464-8DBC9BBF-996D-4880-9B63-64F480C98B77Q36361513-9206CC94-34DD-45F7-ADAB-2B10954BC59AQ36506248-E0EFE786-3A9A-44DB-BAA4-A6F521D7D180Q36765792-16802C19-571F-439E-81E3-FC112C5D8103Q36818867-2735B503-E425-4593-8976-BD548DC7CAC4Q36866618-3DE77B45-EB73-4111-9807-67170F8F163DQ36873506-DD5CAD21-6A02-4C97-BCF3-BEC774D38F9DQ36945337-26CCBEB2-BEF3-4648-8E9E-D678A9751A57Q36971415-AC789E46-2E5C-41F6-AA09-A004A3F63054Q37163981-55B021F8-8DE8-4D6F-AE5A-3390FEAD2AA8
P50
description
onderzoeker
@nl
taighdeoir
@ga
name
Robert A Hauser
@ast
Robert A Hauser
@en
Robert A Hauser
@es
Robert A Hauser
@nl
Robert A. Hauser
@ga
type
label
Robert A Hauser
@ast
Robert A Hauser
@en
Robert A Hauser
@es
Robert A Hauser
@nl
Robert A. Hauser
@ga
prefLabel
Robert A Hauser
@ast
Robert A Hauser
@en
Robert A Hauser
@es
Robert A Hauser
@nl
Robert A. Hauser
@ga